Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium

Rhea-AI Summary

Veracyte (NASDAQ: VCYT) announced the presentation of six abstracts at the 2022 ASCO GU Cancers Symposium, occurring from February 17-19, 2022. The studies focus on the Decipher genomic classifier as a prognostic biomarker for intermediate-risk prostate cancer, marking a significant late-stage validation of gene expression classifiers. The presentations will share insights on risk stratification and treatment guidance for urologic cancers.

The event takes place in San Francisco, Calif..

Positive

• Presentation of six abstracts at a prominent oncology symposium demonstrates ongoing research and validation of the Decipher genomic classifier.
• The phase 3 study validates use of the Decipher genomic classifier for intermediate-risk prostate cancer, indicating potential for improved patient outcomes.

Negative

• None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data for the company’s Decipher urologic cancer tests will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif., and virtually, February 17-19, 2022.

The accepted abstracts include data from a phase 3 study evaluating the Decipher genomic classifier as a prognostic biomarker for patients diagnosed with intermediate-risk prostate cancer from their diagnostic biopsy specimen. This is the first late-stage clinical study validating the use of any gene expression classifier as a prognostic biomarker in this setting.

“At this year’s ASCO GU Symposium we look forward to sharing data from multiple studies that reinforce the ability of our Decipher genomic classifiers to guide more informed, individualized treatment for patients with urologic cancers,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “The findings offer new insights into how our tests may help physicians stratify risk and guide treatment decisions for their patients with prostate, bladder and kidney cancers.”

Below are details of the Veracyte abstracts, which will be presented as posters at the 2022 ASCO GU Cancers Symposium being held at Moscone Center. All poster sessions will take place in Moscone West, Level 1.

Date/Time:		February 17, 2022, 11:30 a.m.-1:00 p.m. PST
Title:		Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126
Presenter:		Daniel E. Spratt, M.D., Case Western Reserve University
Session:		Poster Session A
Date/Time:		February 17, 2022, 11:30 a.m.-1:00 p.m. PST
Title:		Comparative genomic analyses between Asian and Caucasian prostate cancers in an 80,829-patient cohort
Presenter:		Adelene Sim, Ph.D., Duke-NUS Medical School
Session:		Poster Session A
Date/Time:		February 17, 2022, 11:30 a.m.-1:00 p.m. PST
Title:		Transcriptomic Discriminators of Response to Apalutamide in Patients with Prostate Cancer (PC) on Active Surveillance (AS)
Presenter:		Michael Schweizer, M.D., Seattle Cancer Care Alliance
Session:		Poster Session A
Date/Time:		February 17, 2022, 11:30 a.m.-1:00 p.m. PST
Title:		Impact of AR-V7 and other androgen receptor splice variant expression on outcomes of post-prostatectomy salvage therapy
Presenter:		Keisuke Otani, M.D., Ph.D., Massachusetts General Hospital, Harvard Medical School
Session:		Poster Session A
Date/Time:		February 18, 2022, 12:30-2:00 p.m. PST
Title:		BioMarker Analysis and Updated Clinical Follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy
Presenter:		Shilpa Gupta, M.D., Cleveland Clinic
Session:		Poster Session B
Date/Time:		February 19, 2022, 7:00-8:30 a.m. PST
Title:		Prognostic signatures can further stratify clear cell renal carcinoma clinical risk models in the adjuvant setting
Presenter:		Brian Shuch, M.D., University of California, Los Angeles, Institute of Urologic Oncology
Session:		Poster Session C

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the Decipher genomic classifiers. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will" “prospective” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte’s belief that its Decipher classifiers can help stratify patients’ disease risk and assist healthcare providers in making treatment decisions. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 22, 2021 and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, HalioDx, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, Immunoscore, TMExplore, Brightplex, Immunosign, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries and used by Veracyte under license.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005226/en/

Tracy Morris

Vice President of Corporate Communications

& Investor Relations

tracy.morris@veracyte.com

650-380-4413

Source: Veracyte, Inc.

FAQ

What are the key findings of the Veracyte VCYT abstracts presented at ASCO GU 2022?

The abstracts highlight the validation of the Decipher genomic classifier as a prognostic biomarker for intermediate-risk prostate cancer.

When will Veracyte present its research at the ASCO GU Symposium?

Veracyte will present its research from February 17-19, 2022.

What is the significance of the Decipher genomic classifier?

The Decipher genomic classifier is validated as a prognostic biomarker, which may help physicians make more informed treatment decisions for urologic cancer patients.

Where is the ASCO GU Cancers Symposium being held?

The symposium is taking place in San Francisco, California.

What types of cancers are addressed in Veracyte's research?

Veracyte's research addresses urologic cancers, including prostate, bladder, and kidney cancers.